Lixisenatide/insulin glargine: Additional Phase III data

Additional data from the open-label, international Phase III LixiLan-O trial in 1,170 Type II diabetics inadequately controlled on metformin alone or on metformin combined with a second oral anti-diabetic drug showed that

Read the full 327 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE